|
|
||||||||
The Journal of Immunology, Vol 144, Issue 6 2304-2311, Copyright © 1990 by American Association of Immunologists
ARTICLES |
LB Schwartz, TR Bradford, DC Lee and JF Chlebowski
Department of Internal Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.
The catalytic activity of human tryptase, a mast cell neutral endoprotease, is expressed when the enzyme is in its tetrameric form, but is lost under physiologic conditions concomitant with a quaternary structural alteration involving conversion to a monomeric form. The associated changes in the CD spectra noted in the current study indicate accompanying alterations in the secondary structure of the protein. In particular, the progressive disappearance of the negative minimum centered at 228 nm suggests an effect on beta-sheet structure, which may be important for monomer-monomer interaction and/or stabilization of catalytic activity. Dextran sulfate, like heparin, stabilizes the catalytic activity and quaternary structure of tryptase and also maintains the native secondary structure of the enzyme at and beyond a temperature of 40 degrees C. Dextran sulfate-stabilized tryptase therefore was used as an immunogen to which were produced three murine mAb (B2, C11, and G4) recognizing the catalytically active form of the enzyme. Inactive tryptase bound to plastic microtiter wells was not recognized by any of the newly made antibodies, whereas inactive tryptase in solution was recognized by G4, which when biotinylated, could be used as a detector antibody in a sandwich ELISA for tryptase. Each of the newly made mAb recognized the catalytically active form of tryptase. Thus, alterations in epitopes, perhaps reflecting tertiary structural alterations as well as changes in secondary and quaternary conformations, occur with tryptase inactivation. A pragmatic result of these newly generated antibodies is the affinity purification to homogeneity of active tryptase by sequential chromatography with B2 coupled to CH-Sepharose and heparin- agarose. Tryptase purified by this technique had a specific activity with p-tosyl-L-arginine methyl ester of 117 +/- 9 U/mg and had 3.9 +/- 0.3 active sites per molecule of active enzyme (134,000 m.w.) as titrated with p-nitrophenyl-p'-guanidinobenzoate. The spectral and immunologic data in the current study are consistent with concerted conformational alterations in the secondary and tertiary as well as quaternary structures of tryptase associated with loss of catalytic activity. Failure to reverse any of these alterations with dextran sulfate suggests that the pathway of tetramer assembly in vivo is more complicated than simple subunit association.
This article has been cited by other articles:
![]() |
Y. Fukuoka, H.-Z. Xia, L. B. Sanchez-Munoz, A. L. Dellinger, L. Escribano, and L. B. Schwartz Generation of Anaphylatoxins by Human {beta}-Tryptase from C3, C4, and C5 J. Immunol., May 1, 2008; 180(9): 6307 - 6316. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Fukuoka and L. B. Schwartz The B12 Anti-Tryptase Monoclonal Antibody Disrupts the Tetrameric Structure of Heparin-Stabilized beta-Tryptase to Form Monomers That Are Inactive at Neutral pH and Active at Acidic pH. J. Immunol., March 1, 2006; 176(5): 3165 - 3172. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Steinhoff, U. Neisius, A. Ikoma, M. Fartasch, G. Heyer, P. S. Skov, T. A. Luger, and M. Schmelz Proteinase-Activated Receptor-2 Mediates Itch: A Novel Pathway for Pruritus in Human Skin J. Neurosci., July 16, 2003; 23(15): 6176 - 6180. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B. Schwartz, H.-K. Min, S. Ren, H.-Z. Xia, J. Hu, W. Zhao, G. Moxley, and Y. Fukuoka Tryptase Precursors Are Preferentially and Spontaneously Released, Whereas Mature Tryptase Is Retained by HMC-1 Cells, Mono-Mac-6 Cells, and Human Skin-Derived Mast Cells J. Immunol., June 1, 2003; 170(11): 5667 - 5673. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Huang, G. Morales, A. Vagi, K. Chanasyk, M. Ferrazzi, C. Burklow, W.-T. Qiu, E. Feyfant, A. Sali, and R. L. Stevens Formation of Enzymatically Active, Homotypic, and Heterotypic Tetramers of Mouse Mast Cell Tryptases. DEPENDENCE ON A CONSERVED Trp-RICH DOMAIN ON THE SURFACE J. Biol. Chem., January 7, 2000; 275(1): 351 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Burgess, B. J. Newhouse, P. Ibrahim, J. Rizzi, M. A. Kashem, A. Hartman, B. J. Brandhuber, C. D. Wright, D. S. Thomson, G. P. A. Vigers, et al. Potent selective nonpeptidic inhibitors of human lung tryptase PNAS, July 20, 1999; 96(15): 8348 - 8352. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ren, K. Sakai, and L. B. Schwartz Regulation of Human Mast Cell {beta}-Tryptase: Conversion of Inactive Monomer to Active Tetramer at Acid pH J. Immunol., May 1, 1998; 160(9): 4561 - 4569. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |